Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2022

30-08-2022 | Cytostatic Therapy | Peritoneal Surface Malignancy

Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo

Authors: Eun Jung Park, MD, PhD, FACS, Junhyun Ahn, PhD, Sharif Md Abuzar, PhD, Kyung Su Park, PhD, Sung-Joo Hwang, PhD, Seung Hyuk Baik, MD, PhD, FASCRS

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Abstract

Background

Oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) involves mixing oxaliplatin with 5% dextrose solution (5DW) to prevent the structural degradation of oxaliplatin in chloride-containing fluids. This study evaluated oxaliplatin degradation in carrier fluids containing different chloride ion concentrations to determine a carrier fluid that is optimal for use in oxaliplatin-based HIPEC.

Methods

Five types of carrier fluids (normal saline, half saline, 5DW, Dianeal PD-2 peritoneal dialysis solution, and non-chloride Dianeal solution) were compared. An in vitro study was performed that monitored an oxaliplatin concentration of 1 ml (2 mg/ml) oxaliplatin mixed in 24 ml of each carrier fluid during 3 days to evaluate the rate of oxaliplatin degradation in each carrier fluid. An in vivo study, which subjected Sprague-Dawley rats to HIPEC for 60 min, also was performed. The efficacy of each carrier fluid for preserving oxaliplatin was evaluated using area under the curve (AUC) ratios between peritoneal fluid and plasma.

Results

The degradation rate of oxaliplatin in non-chloride fluids was significantly lower than in chloride-containing fluids. However, the rate was less than 10 to 15% at 30 min. The in vivo study indicated that oxaliplatin concentrations in peritoneal fluids did not differ significantly, whereas those in plasma did differ. The AUC ratios of both normal saline and Dianeal were higher than those of 5DW and non-Cl Dianeal solutions.

Conclusions

Chloride-containing fluids, such as normal saline or Dianeal, which display high absorption rates of oxaliplatin and acceptable degradation rates, may be more beneficial for use in oxaliplatin-based HIPEC than 5DW.
Literature
1.
go back to reference Alberto ME, Lucas MF, Pavelka M, Russo N. The degradation pathways in chloride medium of the third-generation anticancer drug oxaliplatin. J Phys Chem B. 2008;112:10765–8.CrossRefPubMed Alberto ME, Lucas MF, Pavelka M, Russo N. The degradation pathways in chloride medium of the third-generation anticancer drug oxaliplatin. J Phys Chem B. 2008;112:10765–8.CrossRefPubMed
2.
go back to reference Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15:2137–45.CrossRefPubMedPubMedCentral Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15:2137–45.CrossRefPubMedPubMedCentral
3.
go back to reference Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1–20.CrossRefPubMed Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1–20.CrossRefPubMed
4.
go back to reference Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nature Rev Clin Oncol. 2010;7:108–15.CrossRef Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nature Rev Clin Oncol. 2010;7:108–15.CrossRef
5.
go back to reference Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109–16.CrossRefPubMedPubMedCentral Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109–16.CrossRefPubMedPubMedCentral
6.
go back to reference Rueth NM, Murray SE, Huddleston SJ, et al. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011;18:174–80.CrossRefPubMed Rueth NM, Murray SE, Huddleston SJ, et al. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011;18:174–80.CrossRefPubMed
7.
go back to reference Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2008;15:535–41.CrossRefPubMed Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2008;15:535–41.CrossRefPubMed
8.
go back to reference Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315–22.CrossRefPubMed Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315–22.CrossRefPubMed
9.
go back to reference Elias D, Raynard B, Bonnay M, Pocard M. Heated intraoperative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol. 2006;32:607–13.CrossRefPubMed Elias D, Raynard B, Bonnay M, Pocard M. Heated intraoperative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol. 2006;32:607–13.CrossRefPubMed
10.
go back to reference Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71.CrossRefPubMed Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71.CrossRefPubMed
11.
go back to reference Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol. 2019;45:400–2.CrossRefPubMed Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol. 2019;45:400–2.CrossRefPubMed
12.
go back to reference Lv ZD, Yang ZC, Wang HB, et al. The cytotoxic effect of TGF-β1 on mesothelial cells via apoptosis in early peritoneal carcinomatosis. Oncol Rep. 2012;27:1753–8.PubMed Lv ZD, Yang ZC, Wang HB, et al. The cytotoxic effect of TGF-β1 on mesothelial cells via apoptosis in early peritoneal carcinomatosis. Oncol Rep. 2012;27:1753–8.PubMed
13.
go back to reference Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomizedsed, open-label, phase 3 trial. Lancet Oncol. 2021;22:256–66.CrossRefPubMed Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomizedsed, open-label, phase 3 trial. Lancet Oncol. 2021;22:256–66.CrossRefPubMed
15.
go back to reference Park EJ, Ahn J, Gwak SW, Park KS, Baik SH, Hwang SJ. Pharmacologic properties of the carrier solutions for hyperthermic intraperitoneal chemotherapy: comparative analyses between water and lipid carrier solutions in the rat model. Ann Surg Oncol. 2018;25:3185–92.CrossRefPubMedPubMedCentral Park EJ, Ahn J, Gwak SW, Park KS, Baik SH, Hwang SJ. Pharmacologic properties of the carrier solutions for hyperthermic intraperitoneal chemotherapy: comparative analyses between water and lipid carrier solutions in the rat model. Ann Surg Oncol. 2018;25:3185–92.CrossRefPubMedPubMedCentral
16.
go back to reference Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303–11.PubMed Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303–11.PubMed
17.
go back to reference Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol. 1985;248(3 Pt 2):F425–35.PubMed Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol. 1985;248(3 Pt 2):F425–35.PubMed
18.
go back to reference Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227–35.PubMed Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227–35.PubMed
19.
go back to reference Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin. J Pharm Sci. 2009;98:3879–85.CrossRefPubMed Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin. J Pharm Sci. 2009;98:3879–85.CrossRefPubMed
20.
go back to reference Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994;54:3500–5.PubMed Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994;54:3500–5.PubMed
21.
go back to reference Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998;10:595–603.PubMed Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998;10:595–603.PubMed
22.
go back to reference Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004;21:891–4.CrossRefPubMed Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004;21:891–4.CrossRefPubMed
23.
go back to reference Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract. 2012;2012:471205.CrossRefPubMedPubMedCentral Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract. 2012;2012:471205.CrossRefPubMedPubMedCentral
24.
go back to reference Torphy RJ, Stewart C, Sharma P, et al. Dextrose-containing carrier solution for hyperthermic intraperitoneal chemotherapy: increased intraoperative hyperglycemia and postoperative complications. Ann Surg Oncol. 2020;27:4874–82.CrossRefPubMed Torphy RJ, Stewart C, Sharma P, et al. Dextrose-containing carrier solution for hyperthermic intraperitoneal chemotherapy: increased intraoperative hyperglycemia and postoperative complications. Ann Surg Oncol. 2020;27:4874–82.CrossRefPubMed
25.
go back to reference Lindsey PT, Martin RCG II, Scoggins CR, et al. Impact of perfusate glucose concentration on perioperative outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2020;256:206–11.CrossRefPubMedPubMedCentral Lindsey PT, Martin RCG II, Scoggins CR, et al. Impact of perfusate glucose concentration on perioperative outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2020;256:206–11.CrossRefPubMedPubMedCentral
26.
go back to reference Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226:434–43.CrossRefPubMedPubMedCentral Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226:434–43.CrossRefPubMedPubMedCentral
27.
go back to reference Mehta AM, Van den Hoven JM, Rosing H, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharmaceutics. 2015;479:23–7.CrossRef Mehta AM, Van den Hoven JM, Rosing H, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharmaceutics. 2015;479:23–7.CrossRef
28.
go back to reference Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.CrossRefPubMed Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.CrossRefPubMed
29.
go back to reference Koh CE, Ansari N, Morris D, Moran B. Beware misrepresentation of PRODIGE 7: danger of throwing out the cytoreductive surgery baby with the hyperthermic intraperitoneal chemotherapy bathwater. ANZ J Surg. 2019;89:992–4.CrossRefPubMed Koh CE, Ansari N, Morris D, Moran B. Beware misrepresentation of PRODIGE 7: danger of throwing out the cytoreductive surgery baby with the hyperthermic intraperitoneal chemotherapy bathwater. ANZ J Surg. 2019;89:992–4.CrossRefPubMed
30.
go back to reference Narasimhan V, Warrier S, Michael M, Ramsay R, Heriot A. Oxaliplatin versus mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study. J Gastrointest Surg. 2020;24:2104–12.CrossRefPubMed Narasimhan V, Warrier S, Michael M, Ramsay R, Heriot A. Oxaliplatin versus mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study. J Gastrointest Surg. 2020;24:2104–12.CrossRefPubMed
31.
go back to reference Kim WR, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Single-center experience with hyperthermic intraperitoneal chemotherapy. Ann Coloproctol. 2017;33:16–22.CrossRefPubMedPubMedCentral Kim WR, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Single-center experience with hyperthermic intraperitoneal chemotherapy. Ann Coloproctol. 2017;33:16–22.CrossRefPubMedPubMedCentral
32.
go back to reference Roh SJ, Park SC, Choi J, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin C used for colorectal peritoneal carcinomatosis. Ann Coloproctol. 2020;36:22–9.CrossRefPubMedPubMedCentral Roh SJ, Park SC, Choi J, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin C used for colorectal peritoneal carcinomatosis. Ann Coloproctol. 2020;36:22–9.CrossRefPubMedPubMedCentral
33.
go back to reference van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44:220–7.CrossRefPubMed van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44:220–7.CrossRefPubMed
34.
go back to reference Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24:179–91.CrossRefPubMed Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24:179–91.CrossRefPubMed
Metadata
Title
Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo
Authors
Eun Jung Park, MD, PhD, FACS
Junhyun Ahn, PhD
Sharif Md Abuzar, PhD
Kyung Su Park, PhD
Sung-Joo Hwang, PhD
Seung Hyuk Baik, MD, PhD, FASCRS
Publication date
30-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12358-7

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue